Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Stuart F.J. Le Grice

Center for Cancer Research National Cancer Institute, USA.

Title: Therapeutic targeting of viral RNAs: High-hanging fruit only needs a longer ladder

Biography

Biography: Stuart F.J. Le Grice

Abstract

Small molecules targeting the enzymes responsible for human immunodeficiency virus (HIV) polyprotein maturation (protease), DNA synthesis (reverse transcriptase) and the subsequent insertion of ribonucleotide-free double-stranded DNA into the host chromosome (integrase) have for several years been the central components of combination antiretroviral therapy. For infected individuals harboring drug-susceptible virus, this approach has afforded complete or near-complete viral suppression. However, in the absence of a curative strategy, the predictable emergence of drug-resistant variants requires continued development of improved antiviral strategies, inherent to which is the need to identify novel targets. Cis-acting regulatory elements of the HIV-1 RNA genome that regulate its transcription (the transactivation response element, TAR), translation (the ribosomal frameshift signal), nucleocytoplasmic transport (the Rev response element or RRE), dimerization (the dimer linkage sequence or DLS), packaging (the  element) and reverse transcription of the (+) strand RNA genome (the primer binding site, or PBS) should now be considered as alternative targets for small molecule, peptide- and oligonucleotide-based therapeutics, as well as combinations thereof. The first part of this talk will summarize how high-resolution 3D structural information is being used to develop small molecule and peptide-based therapeutics that target critical cis-acting RNA motifs of the HIV-1 genome and consequently may be less prone to resistance-conferring mutations. Subsequently, advances in the development of novel high-throughput small molecule microarrays (SMMs) and RNA motifs that have been successfully targeted by this approach will be presented. An extension of the (SMM) approach to target other viral RNAs, or virus-specified RNAs, will be presented. Finally, where target specificity, endosomal release, cellular penetration and toxicity have been the primary obstacle to successful “macromolecule therapeutics”, methodological advances will be reviewed.